Overview
Vanrafia is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval to reduce proteinuria (excess protein in the urine) in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression. Vanrafia’s approval is based on its ability to reduce proteinuria, but per its prescribing information, it is not yet confirmed whether it slows the decline in kidney function. Continued approval may depend on results from future clinical trials. Vanrafia is also known by its drug name, atrasentan.

Vanrafia is an endothelin receptor antagonist. Scientists believe it works by blocking endothelin, a protein that narrows blood vessels and can damage kidneys when overactive. By blocking this protein, Vanrafia may help protect kidney function in people with IgAN.

How do I take it?
Prescribing information states that Vanrafia is taken by mouth as a tablet once daily, with or without food. The recommended dosing schedule for IgAN is once daily. This medication should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Vanrafia include peripheral edema (swelling of the limbs) and anemia (low red blood cell count).

Rare but serious side effects may include hepatotoxicity (liver damage), fluid retention that can lead to weight gain or heart issues, and decreased sperm counts. Vanrafia may cause birth defects and should not be used during pregnancy. Individuals of childbearing potential should use effective contraception before, during, and for two weeks after treatment. Breastfeeding is not advised while using this medication.

For more information about this treatment, visit:

Vanrafia (Atrasentan) Tablets, for Oral Use — Novartis Pharmaceuticals